Peptide Mixing Compatibility Chart: What Can Share a Syringe

Key takeaways

• There is no published compatibility or stability study for any pair of peptides mixed at home. A chart that says two peptides 'can share a syringe' is reporting a habit, not data.
• The only legitimate combinations are the ones a licensed pharmacy prepares, tests and labels as a single product with a beyond-use date. Most online 'stacks' cannot be that, because at least one component (BPC-157, TB-500, KPV, CJC-1295, ipamorelin, MOTS-c, DSIP, injectable GHK-Cu) may not be compounded by any US pharmacy in October 2026.
• Four things change when two solutions meet: pH, preservative concentration, each peptide's stability clock, and sterility. None of them can be judged by looking at the vial.
• Injection-safety guidance is one needle, one syringe, only one time. Two prescribed peptides mean two syringes and two injections; the GLP-1 labels say the same about mixing with insulin.
• The chart below lists the common pairings seen online with their data (none) and the legal status of each component; the dosage chart has the studied doses and the storage guide has the beyond-use rules.

The direct answer

No peptide has been shown to be compatible with any other in a home-mixed syringe, because nobody has published the study. The pairings that circulate, BPC-157 with TB-500, CJC-1295 with ipamorelin, GHK-Cu with everything, were never tested for whether the two molecules survive each other, for what the mixture does to pH or preservative, or for how long it lasts, and most involve at least one compound no US pharmacy may compound, so there is no labeled product to test. The only combinations with a legitimate basis are the ones a licensed pharmacy prepares as a single product under USP General Chapter 797 and labels with a beyond-use date. The peptide dosage chart covers what was studied for each compound on its own, and how to store peptides covers the beyond-use rules a mixture would also have to meet.

Why nobody can tell you two peptides are compatible

Compatibility is not a property of two names. It is a measured property of two specific solutions at a concentration, a pH and a temperature over a time, established by assaying the mixture, and none of that exists for a vial from a website. Five things change when two solutions meet.

pH. Every peptide has a pH range where it is most stable and a point where it is least. Semaglutide, the best-characterized peptide on any clinic menu, degrades fastest between pH 4.5 and 5.5, around its isoelectric point of 5.4, which is why its formulators keep the finished product above pH 7 (Malgave 2025). A second solution with a different buffer, or none, moves the mixture to a pH neither product was designed for, invisibly.

Preservative. Bacteriostatic water contains 0.9 percent benzyl alcohol, and compounded GLP-1 vials and brand multi-dose pens carry benzyl alcohol or phenol of their own. Preservatives are chosen for each product partly on how they affect the active ingredient's shape, which formulators test before approval (Meyer 2007). Mixing dilutes one preservative and doubles another, and the bacteriostatic-water label itself warns that some drugs may be incompatible when combined in the same vehicle or in a vehicle containing benzyl alcohol, tells the user to consult a pharmacist, and says not to store reconstituted solutions unless the drug's manufacturer directs it (Hospira label).

The stability clock. Each labeled product has a beyond-use date derived for that product alone: 7 days for mixed Egrifta WR, 56 days for an Ozempic pen in use, 28 days by convention for a preserved compounded vial. A mixture has no beyond-use date, because nobody measured one, and the shortest clock in it is not necessarily the one that applies.

Sterility. Every transfer between containers is a chance to introduce bacteria, and a mixture that is then stored is a growth medium. The CDC's guidance is that preparing a syringe from two or more sterile medication vials is sterile compounding under USP General Chapter 797, the clean-room standard pharmacies work to, with sterility testing and defined beyond-use dates (CDC). A kitchen counter is not that.

Legality. This is why most of the chart below is empty of data. BPC-157, TB-500, KPV, MOTS-c, CJC-1295, ipamorelin, DSIP, AOD-9604 and injectable GHK-Cu cannot be compounded by any licensed US pharmacy as of October 2026, per our legal tracker. A pharmacy cannot study the stability of a product it may not make, and a vendor of research vials has no reason to. The combinations that could be studied are the ones made of compoundable ingredients, and for those the pharmacy, not the patient, is the party that can do it.

The chart: common pairings seen online

The first column is the stack as it is marketed. The second is the answer to the question this page is named for. The third is from the legal tracker, as of October 9, 2026.

The pattern is hard to miss. The rows with any data at all are the rows where a manufacturer or a pharmacy made the product, and in the one case where a manufacturer studied two injectables together, the instruction was not to mix them.

What pharmacies actually co-formulate

Some combinations do exist as single labeled products, and that distinction from a home mix is the point of this page. These are described as practice, from the compound hubs and the survey above; we found no published stability data for any of them, and the preparing pharmacy is responsible for the beyond-use date.

• GLP-1 drugs with additives. Compounded semaglutide and tirzepatide are commonly dispensed with cyanocobalamin, glycine or niacinamide in the vial; the pharmacy makes the mixture and answers for it. There is no evidence the additives help, and an additive without a clinical rationale does not make the copy legal (FDA).
• PT-141 nasal sprays and alternative strengths. Because federal law bars routinely compounding a copy of Vyleesi, compounded bremelanotide usually arrives as a nasal spray or in a different strength: a pharmacy formulation with a label, at doses no trial has tested, as the PT-141 profile explains.
• NAD+ in combination drips. Intravenous clinics add NAD+ to bags that may also contain vitamins or glutathione, and some pharmacies list NAD+ combinations. Both ingredients are compoundable, the preparer owns the compatibility question, and nobody has published an answer.
• Sermorelin blends, historically. Pharmacies once dispensed sermorelin with a ghrelin-receptor peptide in one vial. Since FDA placed ipamorelin and CJC-1295 in Category 2 in September 2023, any such blend contains a component with no legal source; the CJC-1295 and ipamorelin profile covers what is in the 'blends' still sold.
• Tesamorelin and sermorelin together. Both can be prescribed, as two vials with two labels: brand Egrifta and compounded sermorelin. No pharmacy may lawfully co-formulate them, because putting tesamorelin into a compounded product means compounding a biological product, and biological products are not eligible for the federal compounding exemptions.

A pharmacy product with a label can still be a bad idea; a home mix of two unlabeled vials is not even that.

The single-syringe rule

The CDC's injection-safety guidance for clinicians is built on one sentence, One Needle, One Syringe, Only One Time, and on a set of rules about vials that apply just as well at home (CDC):

• A new sterile syringe and needle for every injection, with nothing reused and nothing shared, even between partners on the same medication.
• Never combine or pool the leftover contents of single-dose vials, and do not keep a single-dose vial for later use.
• Dedicate a multi-dose vial to one person, date it when it is first punctured, and discard it within 28 days unless the manufacturer states another date.
• Do not enter a vial with a syringe or needle that has been used on anyone else, or in any other vial.

The last rule is the one home mixing breaks: drawing peptide A into a syringe and then entering vial B with the same needle carries A into B, and vial B is no longer what its label says for the rest of its life. The GLP-1 manufacturers reached the same conclusion for their own products: the Ozempic label tells patients using insulin to give the two as separate injections and never mix them, in the same body region if they like but not adjacent (Ozempic label). Two prescribed peptides are two syringes, two injections and two sites, which the injection guide covers.

If you are prescribed more than one injectable

• Keep every vial on its own clock, with its date, concentration and beyond-use date written on it, and run each through the calculator separately.
• Inject each with its own syringe, at its own site, in the same body region if you like but not next to each other.
• Tell the prescriber about every injectable you use, including anything bought online; a clinician cannot read a side effect if a third unlabeled vial is in the mix.
• Do not add a research vial to a prescribed regimen; it turns a monitored prescription into an uncontrolled experiment, and the component with no label is the one nobody can account for.

Bottom line

A peptide mixing compatibility chart that tells the truth has one entry: no data. Peptides are compatible when a pharmacy has made them into one product and said so on a label, and incompatible by default everywhere else, because pH, preservative, stability and sterility all change in a mixture and none can be seen. Most stacks sold online fail before any of that matters, since at least one ingredient has no legal source. If you are prescribed two injectables, you own two syringes and two injection sites, and the only thing they should share is a refrigerator shelf.

Frequently asked questions

+−Can you mix two peptides in the same syringe?

Not unless a pharmacy prepared and labeled that combination as one product. There is no published compatibility or stability data for any home-mixed peptide pair, so nobody can tell you whether the two survive each other, what the mixture's pH does to either, or how long it lasts. Injection-safety guidance is one needle, one syringe, one injection, and drawing from two vials into one syringe is compounding, which is a pharmacy's job under USP General Chapter 797.

+−What peptides should not be stacked together?

No stack of research peptides has been studied, so there is no evidence-based list of safe or unsafe combinations, only reasons for caution: two injectables with overlapping mechanisms (two growth hormone secretagogues, two angiogenesis promoters), anything combined with growth hormone or insulin, any stack in someone with a cancer history, and any stack whose components no pharmacy may compound, which in October 2026 is most of them. With two unlabeled vials in one syringe, no side effect can be attributed to anything.

+−What should you not mix with sermorelin?

In the syringe, nothing: sermorelin is reconstituted in its own vial and injected on its own. The blends sold with it, sermorelin with ipamorelin or with CJC-1295, have no stability data and no legal source, because ipamorelin and CJC-1295 were placed in FDA's Category 2 in September 2023 and, though FDA now lists them as nominated but withdrawn, still cannot be compounded. Testosterone cypionate is an oil for intramuscular injection and cannot share an aqueous syringe at all. Pharmacologically, glucocorticoids, untreated hypothyroidism and high blood sugar blunt the growth hormone response, which is a prescriber's question, not a mixing one.

+−Can I use CJC-1295/ipamorelin and tesamorelin together?

There is no study of the combination and no legal way to fill it: tesamorelin exists legally only as the brand Egrifta, and CJC-1295 and ipamorelin cannot be compounded. Tesamorelin and CJC-1295 also act on the same GHRH receptor, so stacking them adds exposure without a new mechanism. A clinician who wants two secretagogues can prescribe tesamorelin and sermorelin as two separate labeled vials, injected separately, and there is still no trial of that pair either.

+−Can CJC-1295/ipamorelin and a GLP-1 be used together?

Clinics market the pair to protect muscle during semaglutide or tirzepatide weight loss. No trial has tested growth hormone secretagogues alongside GLP-1 drugs, and no trial shows that CJC-1295 or ipamorelin preserves lean mass in anyone. The GLP-1 would come from a pharmacy with a label; the secretagogues would be research vials with none. If a clinician wants a secretagogue in that setting, sermorelin is the one a pharmacy can dispense, as a separate injection from a separate syringe.

+−Is there a semaglutide mixing chart?

The only mixing that applies to semaglutide is reconstitution arithmetic, and most compounded semaglutide arrives already in solution. Charts that pair semaglutide with B12, glycine or other additives describe products a pharmacy co-formulated; a 2025 survey found such additives in about half of the unique compounded GLP-1 products on sale, with no evidence that they help and only 18 percent of products stating a beyond-use date. The Ozempic label tells patients never to mix semaglutide and insulin in the same injection, which is the closest thing to an official mixing rule for the molecule.

+−What should you not mix copper peptides with?

For topical GHK-Cu, formulators keep it apart from strong acids and high-dose vitamin C in the same step, because low pH and ascorbate can strip or cycle the copper; alternating them by time of day is the usual workaround. For injectable GHK-Cu the question has no answer, because no human study of the injection exists and no pharmacy may compound it; the GLOW and KLOW blends that put it in one vial with BPC-157 and TB-500 have never been tested for stability or for anything else.

+−Can I mix NAD+ and glutathione in one injection?

Clinics add both to intravenous drips, and some pharmacies list combination preparations; both substances can be compounded, and the pharmacy or clinic that prepares a combination is responsible for its compatibility and its beyond-use date. We found no published compatibility study for the pair. Drawing them together at home from two multi-dose vials is a different act: it is unlicensed compounding, and it removes the one safeguard a labeled product has.

Sources

1. GuidelineCDC. Injection safety: clinical safety guidance for healthcare providers (one needle, one syringe, only one time; single-dose and multi-dose vial rules; preparing a syringe from two or more vials falls under USP 797). Reviewed March 2024. (2024)
2. LabelHospira, Inc. Bacteriostatic Water for Injection, USP, multiple-dose vial. Prescribing information, revised August 2019 (DailyMed). (2019)
3. LabelNovo Nordisk. Ozempic (semaglutide) injection: prescribing information, revised June 2026 (DailyMed setid adec4fd2-6858-4c99-91d4-531f5f2a2d79). (2026)
4. StudyMalgave A et al. Influence of buffering capacity, pH, and temperature on the stability of semaglutide: a preformulation study. J Pept Sci 2025;31:e70039. (2025)
5. ReviewMeyer BK, Ni A, Hu B, Shi L. Antimicrobial preservative use in parenteral products: past and present. J Pharm Sci 2007;96:3155-67. (2007)
6. StudyBelcourt J, Sapowadia A, White CM. Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown. Ann Pharmacother 2026;60:902-6. (2026)
7. StudyArvat E et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001;86:1169-74. (2001)
8. RegulatoryFDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss (compounding after shortage resolution; added ingredients without a clinical rationale do not create a clinical need).
9. RegulatoryFDA. Bulk drug substances nominated for use in compounding under section 503A: Category 1, 2 and 3 lists and updates (updated May 14, 2026). (2026)